PeptiDream Inc.

4587

JP3836750004

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 23/05/2024 BST			5-day change	1st Jan Change
1,884 ^JPY	+0.96%		-3.36%	+26.74%

05-07	Jefferies Adjusts PeptiDream’s Price Target to 1,900 Yen From 1,400 Yen, Keeps at Hold	MT
04-30	Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	CI

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

August 09, 2022 at 07:30 am

PeptiDream Inc. provided updated consolidated revenue guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue to be JPY 24,500 million.

Latest news about PeptiDream Inc.

Jefferies Adjusts PeptiDream’s Price Target to 1,900 Yen From 1,400 Yen, Keeps at Hold	05-07	MT
Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	04-30	CI
PeptiDream Inc. Announces Expansion of Peptide Discovery Collaboration with Novartis Pharma AG	04-30	CI
Certain Preferred Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	03-12	CI
Certain Stock Options of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	03-12	CI
Certain Common Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	03-12	CI
PeptiDream to Partake in Bristol Myers' Tender Offer for All RayzeBio Shares	02-15	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	02-14	CI
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Jefferies Adjusts PeptiDream's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Hold	01-24	MT
Linqmed Inc. announced that it has received ¥680 million in funding from a group of investors	12-21	CI
PeptiDream Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-09	CI
Jefferies Downgrades PeptiDream to Hold From Buy, Adjusts Price Target to 1,300 Yen From 1,600 Yen	27/10/23	MT
PeptiDream and Bristol-Myers Squibb to Explore Alternatives as PDL1 Program Faces Setback	27/10/23	MT
Peptidream Announces Update on PDL1 Program Partnered with Bristol-Myers Squibb Company	26/10/23	CI
Jefferies Upgrades PeptiDream to Buy From Hold, Adjusts Price Target to 1,600 Yen From 1,900 Yen	18/10/23	MT
PeptiDream Inc. Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide- Radioisotope Drug Conjugates	20/09/23	CI
RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million.	14/09/23	CI
PeptiDream Unit Pays 4 Billion Yen Contingent Consideration for AMYViD Indication Change; Shares Down 3%	11/09/23	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	09/08/23	CI
PeptiDream Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	09/08/23	CI
Astellas Pharma Inc. and PeptiDream Inc. Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders	25/07/23	CI
Jefferies Downgrades PeptiDream to Hold From Buy, Adjusts Price Target to 1,900 Yen From 2,200 Yen	18/07/23	MT
PeptiDream Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023	11/05/23	CI

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PeptiDream Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,884 JPY

Average target price

2,750 JPY

Spread / Average Target

+45.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTIDREAM INC.	+26.74%	1.55B
VERTEX PHARMACEUTICALS INCORPORATED	+10.88%	115B
REGENERON PHARMACEUTICALS, INC.	+12.34%	106B
BIONTECH SE	-4.40%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-12.85%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.38%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.27%	12.13B

Bio Therapeutic Drugs

PeptiDream Inc.

Equities

4587

JP3836750004

Biotechnology & Medical Research

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

Latest news about PeptiDream Inc.

Chart PeptiDream Inc.

Company Profile

Income Statement Evolution

Ratings for PeptiDream Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs